Clinical Genitourinary Cancer · Nov 2026

Pre-existing Metabolic Syndrome and Cardiometabolic Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study Using the TriNetX Network

By Schneider J, Prunean J, Wang J et al.

Introduction Metabolic syndrome (MetS) affects approximately one-third of men with metastatic hormone-sensitive prostate cancer (mHSPC). As treatment intensification extends survival, men remain on hormonal therapy longer. We evaluated whether pre-existing MetS identifies men at higher cardiometabolic risk during therapy. Patients and Methods Using the TriNetX US Collaborative Network, we identified 12,818 men with mHSPC who initiated androgen deprivation therapy (ADT) alone (monotherapy) or ADT with an androgen receptor pathway inhibitor or docetaxel (combination therapy) within 3 months of diagnosis. Within each treatment group, MetS+ and MetS− patients were matched 1:1 on age, body mass index, and PSA. The primary outcome was a composite of type 2 diabetes (T2D) diagnosis during follow-up, myocardial infarction, or cerebral infarction; relative risks (RR) and hazard ratios (HR) were estimated. Results After matching, 3,634 monotherapy and 5,394 combination therapy patients were analyzed. MetS was associated with composite cardiometabolic events (monotherapy: RR 4.81, 95% CI 4.19–5.53; combination therapy: RR 4.65, 95% CI 4.15–5.20), T2D diagnosis (RR 12.27 and 10.13), myocardial infarction (RR 2.33 and 2.17), and cerebral infarction (RR 1.96 and 1.85). Among patients without a prior diabetes diagnosis, MetS remained associated with incident T2D (RR 10.18 and 10.29). MetS was not associated with skeletal-related events or PSA progression. MetS was not associated with mortality in the monotherapy group (HR 1.01) and was associated with modestly lower mortality in the combination therapy group (HR 0.87, 95% CI 0.79–0.95). Conclusion Pre-existing MetS identifies men with mHSPC at substantially higher cardiometabolic risk during systemic therapy and supports cardiometabolic assessment and management at treatment initiation. Micro-Abstract In a propensity-matched cohort of 9,028 men with metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy alone or with treatment intensification, pre-existing metabolic syndrome was associated with a 4- to 5-fold higher risk of cardiometabolic events, driven by diabetes, and approximately twofold higher risks of myocardial infarction and cerebral infarction, without worse oncologic outcomes. Cardiometabolic assessment and management are warranted at the start of systemic therapy.

doi.org/10.1016/j.clgc.2026.102708Populations

AgingResearch.News